Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Essential role for Ras signaling in glioblastoma maintenance.

Holmen SL, Williams BO.

Cancer Res. 2005 Sep 15;65(18):8250-5.

2.
3.

Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN.

Nat Genet. 2000 May;25(1):55-7.

PMID:
10802656
4.

Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis.

Uhrbom L, Kastemar M, Johansson FK, Westermark B, Holland EC.

Cancer Res. 2005 Mar 15;65(6):2065-9.

5.

GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background.

Hede SM, Hansson I, Afink GB, Eriksson A, Nazarenko I, Andrae J, Genove G, Westermark B, Nistér M.

Glia. 2009 Aug 15;57(11):1143-53. doi: 10.1002/glia.20837.

PMID:
19115382
6.

Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis.

Ferletta M, Uhrbom L, Olofsson T, Pontén F, Westermark B.

Mol Cancer Res. 2007 Sep;5(9):891-7.

7.

Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.

Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL.

Neuro Oncol. 2012 Jan;14(1):34-42. doi: 10.1093/neuonc/nor184. Epub 2011 Oct 20.

8.

Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity.

Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH.

Cancer Res. 2008 Feb 1;68(3):724-30. doi: 10.1158/0008-5472.CAN-07-2291.

9.

APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.

Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S.

Gastroenterology. 2006 Oct;131(4):1096-109. Epub 2006 Aug 16. Erratum in: Gastroenterology. 2006 Dec;131(6):2029.

PMID:
17030180
10.
11.

Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization.

Chiappetta G, Fabien N, Picone A, Califano D, Monaco C, de Franciscis V, Vecchio G, Santelli G.

Oncol Res. 1996;8(2):85-93.

PMID:
8859779
13.

Akt signaling is required for glioblastoma maintenance in vivo.

Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL.

Am J Cancer Res. 2011;1(2):155-167.

14.

A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors.

Seidler B, Schmidt A, Mayr U, Nakhai H, Schmid RM, Schneider G, Saur D.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10137-42. doi: 10.1073/pnas.0800487105. Epub 2008 Jul 11.

15.

Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.

Janzarik WG, Kratz CP, Loges NT, Olbrich H, Klein C, Schäfer T, Scheurlen W, Roggendorf W, Weiller C, Niemeyer C, Korinthenberg R, Pfister S, Omran H.

Neuropediatrics. 2007 Apr;38(2):61-3.

PMID:
17712732
17.

Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.

Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, Hess K, Fuller GN, Zhang W.

Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3475-80. doi: 10.1073/pnas.1120375109. Epub 2012 Feb 15.

18.

Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.

Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG.

Cancer Res. 2006 Aug 1;66(15):7445-52.

20.

Modeling and preclinical trials for gliomas.

Salpietro M, Holland EC.

Clin Neurosurg. 2005;52:104-11. No abstract available.

PMID:
16626060

Supplemental Content

Support Center